Subsensitivity of human β-adrenergic adenylate cyclase after salbutamol treatment of depression

B. Lerer, R. P. Ebstein, R. H. Belmaker

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Although numerous studies have suggested that depression may be associated with a reduction in synaptic noradrenaline in the brain, direct β-adrenergic receptor agonists have only recently been tested in the treatment of depression. Moreover, newer theories of antidepressant action suggest that a reduction in β-adrenergic receptor sensitivity is a better correlate of antidepressant treatment than noradrenaline turnover changes. Eleven depressed patients were treated with salbutamol, a β-2-adrenergic agonist, and β-2-adrenergic receptor sensitivity was evaluated before, during, and after treatment. β-Adrenergic receptor sensitivity was evaluated by measuring the plasma cyclic AMP increase after an IV dose of salbutamol. The β-adrenergic agonist exhibited antidepressant efficacy and induced subsensitivity of the β-adrenergic adenylate cyclase with a time course paralleling the antidepressant effects. The results support the concept that receptor sensitivity changes occur during antidepressant therapy.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
Issue number2
StatePublished - 1 Nov 1981
Externally publishedYes


  • Adenylate cyclase
  • Depression
  • Salbutamol
  • Subsensitivity


Dive into the research topics of 'Subsensitivity of human β-adrenergic adenylate cyclase after salbutamol treatment of depression'. Together they form a unique fingerprint.

Cite this